Assembly Biosciences Presents New Data Highlighting Entry Inhibitor and Core Inhibitor Programs at EASL’s International Liver Congress™ 2023
June 21, 2023 08:00 ET
|
Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral...
Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL International Liver Congress™ 2023
June 07, 2023 08:00 ET
|
Assembly Biosciences, Inc.
-- International Herpesvirus Workshop will feature oral and poster presentations of preclinical data from ABI-5366, Assembly Bio’s first herpesvirus development candidate -- -- Five posters accepted...
VBI Vaccines Announces Late-Breaking Poster Presentation at EASL 2019
April 09, 2019 08:00 ET
|
VBI Vaccines, Inc.
Poster presentation to highlight data from three previously-conducted clinical studies of Sci-B-Vac®, VBI’s prophylactic Hepatitis B vaccineIn all three studies, seroprotection rates of more than 98%...
Galectin Therapeutics launches the Liver Line, an online community and publication on liver health and liver disease
May 03, 2017 08:30 ET
|
Galectin Therapeutics
NORCROSS, Ga., May 03, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced the launch of the Liver...
Galectin Therapeutics and Exalenz to Present Late-Breaking Abstract at The International Liver Congress™ 2017
April 18, 2017 08:00 ET
|
Galectin Therapeutics
NORCROSS, Ga., April 18, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, and Exalenz Bioscience (TASE:EXEN),...
Assembly Biosciences to Present Data at The International Liver Congress(TM) 2016 that Supports Advancing Its CpAM Candidates into HBV Clinical Trials
April 13, 2016 07:00 ET
|
Assembly Biosciences, Inc.
—In Preclinical Studies, Novel Class of Core Protein Allosteric Modifiers (CpAMs) Showed Potent Antiviral Activity, No Cytotoxicity and Good Pharmacokinetic Properties— —Planning to Start Phase 1...
Assembly Biosciences to Present Data on New Series of HBV Core Protein Allosteric Modifiers at The International Liver Congress™ 2016
March 30, 2016 07:30 ET
|
Assembly Biosciences, Inc.
BARCELONA, Spain and NEW YORK, March 30, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a public biotechnology company advancing a new class of oral biologic therapeutics for...
OnCore Biopharma Licenses Second-Generation Cyclophilin Inhibitors From NeuroVive for the Treatment of Chronic HBV Infection
September 09, 2014 03:00 ET
|
OnCore Biopharma, Inc.
OnCore Secures Exclusive Worldwide Rights to NVP018
NVP018 Will Complement OnCore's Existing Pipeline Directed at Achieving All-Oral Cure for HBV
DOYLESTOWN, Pa., Sept. 9, 2014 (GLOBE NEWSWIRE)...